Associated Papers
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_4.xlsx › ERBB4_mutations
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM et al.
Pharmacological Reviews, 2022
Genomic alterations of ERBB receptors in cancer: clinical implications.
Mishra R et al.
Oncotarget, 2017
ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C et al.
Methods in Molecular Biology (clifton, N.j.), 2014
The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China.
Zhou QM et al.
Chinese Journal of Cancer, 2013
Select a paper to view details